Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the
biweekly pegfilgrastim support, in order to further improve upon the effectiveness and
favorable toxicity of this triplet.